FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
You may also be interested in...
Drug Name Battles May Be Waged More Publicly; FDA Petitioned On Zentase
FDA's efforts to pre-empt trade name conflicts by shifting decisions to earlier in the application process are still just getting off the ground. In one case, though, a company has taken matters into its own hands and is pressing the agency to make an early, public determination about whether a proposed brand name is acceptable
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program